← The SEC Ephemeris: the whole map
Janssen Biotech, Inc. amivantamab hyaluronidase
In the graph: all 1 documents (3 pages).
- Application
- BLA 761433
- Ticker
- Janssen Biotech, Inc.
- Product
- amivantamab hyaluronidase
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- December 13, 2024
From FDA letters and SEC filings. Not investment or medical advice.